YANISH ADITYA MAHENDRA, 051311133236 (2017) STUDI PENGGUNAAN OBAT PADA PASIEN ANAK DENGAN KAWASAKI SYNDROME (Penelitian di IRNA Anak SMF Ilmu Kesehatan Anak RSUD Dr. Soetomo Surabaya). Skripsi thesis, Universitas Airlangga.

Preview	Text (ABSTRAK) FF FK 33-17 Mah s Abstrak.pdf Download (74kB) | Preview
	Text (FULLTEXT) FF FK 33-17 Mah s Sec.pdf Restricted to Registered users only until 27 October 2020. Download (1MB) | Request a copy

Abstract

Kawasaki Syndrome is an acute, self-limited vasculitis of unknown etiology that occurs predominantly in infants and young children. Kawasaki Syndrome was first described in 1967 by Tomisaku Kawasaki and characterized by fever, bilateral nonexudative conjunctivitis, erythema of the lips and oral mucosa, changes in the extremities, rash, and cervical lymphadenopathy. The goal of Kawasaki Syndrome drug therapy is directed at reducing inflammation in the coronary artery wall, and preventing coronary thrombosis therefore the main therapy in this case is IVIG, acetosal and corticosteroid. This study aimed to analyze the profile of drug use in patient with Kawasaki Syndrome including the type of drug, dosage and route of administration, and to identify drug related problems (DRP) that might be occurred in therapy. The study was conducted retrospectively to analyze drug used in the period January 2013 until December 2016 in Pediatric Ward of Dr. Soetomo Teaching Hospital Surabaya. This study had been reviewed by Ethics Committee of Dr. Soetomo Teaching Hospital. The most used drug in therapy of Kawasaki Syndrome were acetosal with dose of 80-100 mg/kg of body weight as anti-inflammatory agent and dose of 3-5 mg/kg of body weight as antiplatelet agent in 15 patients (94%), IVIG with dose of 2 g/kg of body weight in 8 patients (50%) and corticosteroids with dose of 10-30 mg/kg of body weight as immunosuppressive agent in 7 patients (44%). Drug used in Kawasaki Syndrome didn’t show any actual adverse effect however monitoring on drug used in Kawasaki Syndrome should have done related to any potential drug adverse effect in Kawasaki Syndrome therapy. Drug utilization including the type, dose, route and frequency of drug administration in patients with Kawasaki Syndrome in Dr. Soetomo Teaching Hospital was appropriate based on Kawasaki Syndrome guidelines.

Actions (login required)

View Item